C
0.120
-0.01 (-4.00%)
| Previous Close | 0.125 |
| Open | 0.125 |
| Volume | 17,654 |
| Avg. Volume (3M) | 47,244 |
| Market Cap | 21,555,840 |
| Price / Book | 7.26 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2024 - 1 Mar 2024 |
| Operating Margin (TTM) | 2,472.77% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | 41.40% |
| Current Ratio (MRQ) | 5.58 |
| Operating Cash Flow (TTM) | -9.96 M |
| Levered Free Cash Flow (TTM) | -6.61 M |
| Return on Assets (TTM) | -46.70% |
| Return on Equity (TTM) | -81.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CYNATA THR FPO | - | - |
AIStockmoo Score
1.8
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.82% |
| % Held by Institutions | 14.69% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |